Kintara Therapeutics Inc expected to post a loss of 15  cents a share - Earnings Preview

TuHURA Biosciences

10/05/2022 03:05

* Kintara Therapeutics Inc  KTRA.OQ   KTRA.O  is expected
to show
no change in quarterly revenue when it reports  results on May
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Kintara
Therapeutics Inc
is for a loss of 15 cents per share. For the same quarter last
year, the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kintara
Therapeutics Inc is $3​, above​ its last closing price of $0.18.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.17       -0.16      -0.12     Beat    25
 Sep. 30 2021  -0.15       -0.14      -0.17     Missed  -17.2
 Jun. 30 2021  -0.14       -0.16      -0.13     Beat    18.8​
 Mar. 31 2021  -0.20       -0.18      -0.23     Missed  -26
 ​​Dec.        -0.14       -0.14      -0.22     Missed  -54.4
 31 2020                                                
 Sep. 30 2020  -0.09       -0.09      -0.20     Missed  -122.2
                                                        ​
 Jun. 30 2020  -0.09       -0.12      -0.33     Missed  -182.8
 Mar. 31 2020              -0.12      -0.17     Missed  -36
 This summary was machine generated May 10 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated